CRC Appoints Jason Casarella, MBA as Chief Commercial Officer
Experienced CRO executive joins Cognitive Research Corporation to expand partnerships and strengthen its position as a leading CRO for CNS clinical trials
"Jason's proven experience leading high-performing teams and forging strategic partnerships will be instrumental as CRC continues to advance our work with sponsors to bring new CNS therapies closer to approval," said
Prior to joining CRC,
"I am honored to join CRC at such an important time in the company's growth," said
With
About Cognitive Research Corporation
Cognitive Research Corporation (CRC) is a leading full-service clinical research organization, specializing exclusively in CNS disorders, including neurology, psychiatry, and analgesia. Combining innovative technology, deep scientific expertise, and personalized concierge support, CRC partners with sponsors, specialized sites, and CNS experts to deliver high-quality, efficient clinical trials across Phase I-III. Guided by a commitment to consistency, urgency, and accuracy, we help bring new therapies through rigorous testing to FDA approval, ultimately improving patient outcomes. Learn more at www.cogres.com.
Media Contact:
Director of Marketing, CRC
[email protected] | +1 (910) 742-5528
View original content to download multimedia:https://www.prnewswire.com/news-releases/crc-appoints-jason-casarella-mba-as-chief-commercial-officer-302542704.html
SOURCE Cognitive Research Corporation
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- More than 160,000 Duke Energy customers in Ohio and Kentucky remain without power as second round of storms is expected
- Hearts At Home Companion Care Introduces Companion Care in Washington, OK
- Canyon GBS Ranks No. 126 on the 2026 Inc. 5000 and No. 11 Among America’s Fastest-Growing Software Companies
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share